Higher concentrations of ROS accelerated the release of bFGF from the hydrogel in vitro, and the therapeutic effects of the ROS-responsive hydrogel loaded with bFGF were validated using mouse and pig models of ischemia–reperfusion injury [337]. This evidence concerns the gene FGF2 and ischemia reperfusion injury.